Identification of biomarkers in multiple myeloma: A comprehensive study combining microarray analysis and Mendelian randomization
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18504 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Yidong Zhu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traditional Chinese Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Mendelian Randomization Analysis, Protein Interaction Maps, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Facility for Translational Medicine (Shanghai), Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Despite remarkable advancements in the treatment of multiple myeloma (MM), relapse remains a challenge. However, the mechanisms underlying this disease remain unclear. This study aimed to identify potential biomarkers that could open new avenues for MM treatment. Microarray data and clinical characteristics of patients with MM were obtained from the Gene Expression Omnibus database. Differential expression analysis and protein–protein interaction (PPI) network construction were used to identify hub genes associated with MM. Predictive performance was further assessed using receiver operating characteristic curves and nomogram construction. Functional enrichment analysis was conducted to investigate possible mechanisms. Mendelian randomization (MR) was used to evaluate the causal relationship between the crucial gene and MM risk. Topological analysis of the PPI network revealed five hub genes associated with MM, with myeloperoxidase ( MPO ) being the key gene owing to its highest degree and area under the curve values. MPO showed significant differences between patients with MM and controls across all datasets. Functional enrichment analysis revealed a strong association between MPO and immune‐related pathways in MM. MR analysis confirmed a causal relationship between MPO and the risk of MM. By integrating microarray analysis and MR, we successfully identified and validated MPO as a promising biomarker for MM that is potentially implicated in MM pathogenesis and progression through immune‐related pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Traditional Chinese Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Endocrinology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.
ORCID-Profile: Yidong Zhu
Förderung
- the National Facility for Translational Medicine (Shanghai)
- Shanghai Municipal Health Commission
Zitieren
APA
Zhu, Y., Liu, J., & Wang, B. (2024). Identification of biomarkers in multiple myeloma: A comprehensive study combining microarray analysis and Mendelian randomization. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18504
Vancouver
Zhu Y, Liu J, Wang B. Identification of biomarkers in multiple myeloma: A comprehensive study combining microarray analysis and Mendelian randomization. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18504
BibTeX
@article{Zhu2024,
author = {Zhu, Yidong and Liu, Jun and Wang, Bo},
title = {Identification of biomarkers in multiple myeloma: A comprehensive study combining microarray analysis and Mendelian randomization},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18504}
}
EUVIMED